Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Drawn and quartered

Biotech winners, losers in 3Q15

There was no joy to be had in 3Q15, as every biotech market cap band fell by at least 15%. After the carnage only one group - companies valued north of $5 billion - are in the black for the year.

The big caps are clinging to a 0.2% gain through the first nine months of the year despite shedding 15.1% in the third quarter (see "Results by Market Cap," page 15).

Biotechs in the top band that posted gains included Incyte Corp. and Genmab A/S. Incyte finished the quarter with consecutive days of good news. On Sept. 29, the company and partner Eli Lilly and Co. said baricitinib met the primary endpoint in a Phase III trial to treat rheumatoid arthritis (RA). Additional Phase III trials of the oral Janus kinase-1 (JAK-1) and JAK-2 inhibitor are expected to read out this quarter.

On Sept. 30, Incyte said it will join the NASDAQ-100 Index, effective Oct. 7.

All told, Incyte finished 3Q15 with a 6% gain. For the year, the company is up 51% and is the best-performing biotech stock in the top market tier.

Genmab posted a 5% gain in 3Q15, thanks largely to news in August that results from a Phase I/II trial of its daratumumab (HuMax-CD38) for multiple myeloma (MM) were published in theNew England Journal of Medicine.

The antibody against CD38 is partnered with Johnson & Johnson's Janssen Research & Development LLC unit and under FDA review for MM with a March 9 PDUFA date.

The worst performer in the top

Read the full 2583 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers